Pipeline competition such as Yuhan Corporation and Hanmi Pharm
Global stage knock by differentiation of small and medium -sized biomles and mechanisms
(Seoul = News1) Jang Do -min reporter = As the global obesity treatment market has expanded rapidly, the movement of domestic pharmaceutical bio companies is also accelerating. Yuhan Corp., Hanmi Pharm, Daewoong Pharm, HK Innoen, Metropolis, D & D Pamatech, and Inventory Lab, aimed at the current GLP-1 series treatment market led by Novo No Disc and Eli Lily, are introducing pipelines.
They don’t just follow. We are using a strategy of setting up different mechanisms, formulations, and target patients to dig a gap. Yuhan Corporation developed a double agent that combines GLP-1 and FGF21, but this material was returned from the Bering Gelheim. Currently, it is reported that it is continuing preclinical research in the United States and Europe.
According to the industry on the 30th, Hanmi Pharmaceutical has started again around Epeglena Tide, a large new drug project. After the export of technology in the past, the company continued to re -challenge with the three -phase global clinical trials. It is considered one of the most advanced companies among domestic companies as it is open to weight loss and blood sugar control, as well as expansion of indications to cardiovascular and kidney diseases.
Daewoong Pharm is speeding up the development of a double agent that aims at GLP-1 and GIP at the same time. Although the clinical results have not yet been disclosed, the company is planning a simultaneous strategy of obesity and metabolic syndrome based on patent applications and mechanism development.
HK Innoen has been approved for Phase III clinical trials for Echogluide based on cooperation with Chinese companies. On the second and third phase of China, the weight loss effect was higher than that of Saxenda.
Metibai (Dong-A ST subsidiary) is attracting attention as the DA-1726, which confirmed the weight loss effect of up to 6.3% in four weeks. The GLP-1 and Glucagon’s double-action mechanisms are made with a differentiation strategy that encompasses Semagluide intolerance patients.
D & D Pamatec is developing a dual agent that can be administered oral. Oralink maximizes the convenience of formulation through its own platform and has entered the US clinical trial. Some global technology transfer has also been carried out.
Inventory Lab is developing a sustainable injection formulation that can extend the medication cycle at least once a month. Based on the technology that precisely control the release of drugs, it is a strategy to capture patient convenience and compliance at the same time.
In this way, domestic companies that are approaching in different ways are quiet but steadily accumulating. For example, this month’s Bio USA in Boston, USA, showed that domestic companies are showing up their obesity treatment technology to keep up with the flow.
An official of the pharmaceutical industry said, “Many of the domestic companies are initially aiming to transfer technology, but to lead the actual contract, significant clinical progress and design completion are required.”
Another official said, “The GLP-1 series is not only the efficacy of drugs but also the convenience and safety of the formulation, so it is not competitive to imitate the mechanism.”
Meanwhile, it is receiving a lot of attention because of being an obesity treatment technology development company, but there are skeptical gaze on some companies that are attracting attention only for technology transfer expectations. In fact, some companies have risen initial consultations with global pharmaceutical companies, and have been plunging since their expectations have been turned off. It is pointed out that the agreement and the point of view are still uncertain.
jdm@news1.kr
